NCT00464113View on ClinicalTrials.gov

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

April 30, 2011

Conditions
Chronic Myeloid LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions
DRUG

XL228

1-hour IV infusion

Trial Locations (6)

20007

Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington D.C.

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

48109

University of Michigan Health System, Ann Arbor

77030

MD Anderson Cancer Center, Houston

90095-1678

UCLA School of Medicine, Los Angeles

94143-1270

University of California San Francisco, San Francisco

Sponsors

Lead Sponsor

Exelixis
All Listed Sponsors
lead

Exelixis

INDUSTRY